ARID2 deficiency promotes tumor progression and is associated with higher sensitivity to PARP inhibition in lung cancer
T. Moreno, L. Gonzalez-Silva, B. Monterde, I. Betancor-Fernandez, C. Revilla, A. Agraz-Doblas, J. Freire, P. Isidro, L. Quevedo, S. Montes-Moreno, L. Cereceda, A. Astudillo, B. Casar, P. Crespo, C. Morales Torres, , I. Varela
This study identifies ARID2 deficiency in 20% of lung cancer patients, showing it promotes tumor progression and increases sensitivity to PARP inhibition.
bioRxiv · Jan 10, 2020Cancer Biology